Proteomic and Phosphoproteomic Maps of Lung Squamous Cell Carcinoma From Chinese Patients

doi:10.3389/fonc.2020.00963

	Proteomic and Phosphoproteomic Maps of Lung Squamous Cell Carcinoma From Chinese Patients
	Pan, Lulu 2,3; Wang, Xijun 4; Yang, Longhai 1,5; Zhao, Lei 2; Zhai, Linhui 2; Xu, Junyu 2; Yang, Yikun 1; Mao, Yousheng 1; Cheng, Shujun 4; Xiao, Ting 4
刊名	FRONTIERS IN ONCOLOGY
	2020-06-16
卷号	10 页码:13
关键词	lung squamous cell carcinoma proteomics phosphoproteomics clustering lymph node metastasis cell cycle
ISSN号	2234-943X
DOI	10.3389/fonc.2020.00963
通讯作者	Xiao, Ting(xiaot@cicams.ac.cn) ; Tan, Minjia(mjtan@simm.ac.cn)
英文摘要	Lung squamous cell carcinoma (LUSC) is one of the leading causes of tumor-driven deaths in the world. To date, studies on the tumor heterogeneity of LUSC at genomic level have only revealed limited therapeutic benefits. Therefore, system-wide research of LUSC at proteomic level may further improve precision medicine strategies on individual demands. To this end, we performed proteomic and phosphoproteomic study for LUSC samples of 25 Chinese patients. From our results, two subgroups (Cluster I and II) based on proteomic data were identified, which were associated with distinct molecular characteristics and clinicopathologic features. Combined with phosphoproteomic data, our result showed that spliceosome pathway was enriched in Cluster I, while focal adhesion pathway, immune-related pathways and Ras signaling pathway were enriched in Cluster II. In addition, we found that lymph node metastasis (LNM) was associated with our proteomic subgroups and cell cycle pathway was enriched in patients with LNM. Further analysis showed that MCM2, a DNA replication licensing factor involved in cell cycle pathway, was highly expressed in patients with poor prognosis, which was further proved by immunohistochemistry (IHC) analysis. In summary, our study provided a resource of the proteomic and phosphoproteomic features of LUSC in Chinese patients.
资助项目	Natural Science Foundation of China[81872888] ; Natural Science Foundation of China[81821005] ; National Basic Research Program of China (973 Program)[2014CBA02004] ; National Science and Technology Major Project Key New Drug Creation and Manufacturing Program[2018ZX09711002-004] ; CAMS Innovation Fund for Medical Sciences (CIFMS) of China[2016-I2M1-001] ; CAMS Innovation Fund for Medical Sciences (CIFMS) of China[2019-I2M-1-003] ; National Key Research and Development Program of China[2017YFC0908401] ; Innovation research team of high-level local universities in Shanghai[SSMU-ZDCX20181202] ; K. C. Wong Education Foundation
WOS关键词	CANCER STATISTICS ; EXPRESSION ; REVEALS ; PHOSPHORYLATION ; BIOSYNTHESIS ; ENRICHMENT ; MUTATIONS ; PROTEINS ; TARGET ; GENES
WOS研究方向	Oncology
语种	英语
出版者	FRONTIERS MEDIA SA
WOS记录号	WOS:000546878000001
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/291821]
专题	中国科学院上海药物研究所
通讯作者	Xiao, Ting; Tan, Minjia
作者单位	1.Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr,Dept Thorac Surg, Beijing, Peoples R China 2.Chinese Acad Sci, Chem Prote Ctr, Shanghai Inst Mat Media, State Key Lab Drug Res, Shanghai, Peoples R China 3.Univ Chinese Acad Sci, Sch Pharm, Beijing, Peoples R China 4.Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr,Dept Etiol & Carcinogenesis,State K, Beijing, Peoples R China 5.Shenzhen Univ, Clin Med Acad, Gen Hosp, Dept Cardiothorac Surg, Shenzhen, Peoples R China
推荐引用方式 GB/T 7714	Pan, Lulu,Wang, Xijun,Yang, Longhai,et al. Proteomic and Phosphoproteomic Maps of Lung Squamous Cell Carcinoma From Chinese Patients[J]. FRONTIERS IN ONCOLOGY,2020,10:13.
APA	Pan, Lulu.,Wang, Xijun.,Yang, Longhai.,Zhao, Lei.,Zhai, Linhui.,...&Tan, Minjia.(2020).Proteomic and Phosphoproteomic Maps of Lung Squamous Cell Carcinoma From Chinese Patients.FRONTIERS IN ONCOLOGY,10,13.
MLA	Pan, Lulu,et al."Proteomic and Phosphoproteomic Maps of Lung Squamous Cell Carcinoma From Chinese Patients".FRONTIERS IN ONCOLOGY 10(2020):13.